A

AKTS

AKTS

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
55%Neutral
Buy/Sell Ratio97% buys
BearishBullish
AKTS Live QuoteReal-time
$16.15
$0.61(-3.64%)1M
Day Range$15.99 – $16.73
Open$16.32
Previous Close$16.40
Volume374.8K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$898.35M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-1.80
Price to Book2.0
Dividend Yield0.65%
Beta (Volatility)1.18
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $16.15 (11%)
Low: $13.96High: $34.19
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$35.88-76.1% upside

Insider Buys

6

$114.31M

Insider Sales

5

$3.23M

Total Volume

$117.54M

11 transactions

Net Activity

+$111.08M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
100CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Strong buying bias: purchases represent 97% of total transaction value.
  • •Cluster buying: 6 unique insiders purchased shares, showing strong alignment.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
E
1

Ecor1 Capital, LLC

Dir

1 buys0 sells

$40.00M total

M
2

Mpm Bioventures 2018, L.P.

10%

1 buys0 sells

$20.03M total

G
3

Gadicke Ansbert

10%

1 buys0 sells

$20.03M total

V
4

Vida Ventures Ii, LLC

10%

1 buys0 sells

$15.03M total

K
5

Kim Helen Susan

Dir, 10%

1 buys0 sells

$15.03M total

Trading History
AKTS insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 23, 2026

1 months ago

Czibere Akos

Chief Medical Officer

C-Level
Sell12.5K$20.69$259K

Jul 20, 2026

4 months ago

Herrmann Ken

Dir

Director
Sell4.9K$24.56$119K

Jul 17, 2026

4 months ago

Herrmann Ken

Dir

Director
Sell3.1K$25.21$77K

Jul 8, 2026

4 months ago

Ron-Bigger Shulamit

COO

COO
Sell50.0K$27.75$1.39M

Jul 8, 2026

4 months ago

Czibere Akos

Chief Medical Officer

C-Level
Sell50.0K$27.77$1.39M

Jan 12, 2026

10 months ago

Foley Todd

Dir, 10%

Director
Buy232.9K$18.00$4.19M

Jan 12, 2026

10 months ago

Mpm Bioventures 2018, L.P.

10%

10% Owner
Buy1.11M$18.00$20.03M

Jan 12, 2026

10 months ago

Gadicke Ansbert

10%

10% Owner
Buy1.11M$18.00$20.03M

Jan 12, 2026

10 months ago

Ecor1 Capital, LLC

Dir

Director
Buy2.22M$18.00$40.00M

Jan 12, 2026

10 months ago

Vida Ventures Ii, LLC

10%

10% Owner
Buy835.0K$18.00$15.03M

Jan 12, 2026

10 months ago

Kim Helen Susan

Dir, 10%

Director
Buy835.0K$18.00$15.03M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
AKTS Buy Conviction97%
Industry Rank#0 of 569
Volume Contribution0.7%
Total Industry Activity$16.52B

AKTS has an insider buy conviction of 97%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for AKTS

Over the last 90 days, corporate insiders at AKTS (AKTS) engaged in a total of 11 transactions reported via SEC Form 4 filings. Among these, 6 were open-market purchases and 5 were sales. The total volume of insider trading reached $117.54M.

The net insider activity for AKTS shows a net buying bias of $111.08M. This activity represents a 97% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Ecor1 Capital, LLC (Dir), who traded 2.22M shares valued at $40.00M on Jan 12, 2026.

Live Market News & Developments
Aggregated real-time headlines for AKTS (AKTS)
6 updates

Aktis Oncology (NASDAQ:AKTS) Stock: Research Spending and a Large Cash Balance Define the Quarter

kalkine.ca4d ago

Paul L. Feldman of Aktis Oncology (AKTS) exercises options on 55,035 shares at $1.9022 per share.

Stock Titan20h ago

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound

Yahoo Finance179d ago

Aktis is a Strong Buy at Raymond James on therapeutic platform

Seeking Alpha157d ago

Aktis Oncology (NASDAQ:AKTS) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

MarketBeat5d ago

Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance

Benzinga54d ago

FAQs About AKTS Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for AKTS.

Based on SEC Form 4 disclosures, the Insider Confidence Score for AKTS is currently 100/100, which reflects a strong accumulation bias. This calculation accounts for a total of 6 purchases and 5 sales by company executives over the last 90 days.

The CEO Conviction Index for AKTS is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.